Dr. Atreya on How the NCCN Guidelines Have Impacted Treatment Options in mCRC

Chloe E. Atreya, MD, PhD
Published: Wednesday, Mar 14, 2018



Chloe E. Atreya, MD, PhD, assistant clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the molecular subgroups in metastatic colorectal cancer (mCRC) and viable treatment options for patients with microsatellite instability (MSI)-high and BRAF-mutated cancers.

Subgroups include patients who have MSI-high and BRAF-mutated tumors. The CheckMate-142 study combined nivolumab (Opdivo) with or without ipilimumab (Yervoy). The combination in that study yielded a 55% overall response rate and 80% disease control rate.

For BRAF-mutated tumors, the 2018 National Comprehensive Cancer Network (NCCN) guidelines now include the S1406 strategy. The study looked at the use of irinotecan plus cetuximab (Erbitux) and vemurafenib (Zelboraf) as a potential option for these patients in the second-line setting. Although it is not FDA approved, its inclusion in the NCCN guidelines will make it more available for patients with BRAF-mutated colon cancers to receive vemurafenib.
 
SELECTED
LANGUAGE


Chloe E. Atreya, MD, PhD, assistant clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the molecular subgroups in metastatic colorectal cancer (mCRC) and viable treatment options for patients with microsatellite instability (MSI)-high and BRAF-mutated cancers.

Subgroups include patients who have MSI-high and BRAF-mutated tumors. The CheckMate-142 study combined nivolumab (Opdivo) with or without ipilimumab (Yervoy). The combination in that study yielded a 55% overall response rate and 80% disease control rate.

For BRAF-mutated tumors, the 2018 National Comprehensive Cancer Network (NCCN) guidelines now include the S1406 strategy. The study looked at the use of irinotecan plus cetuximab (Erbitux) and vemurafenib (Zelboraf) as a potential option for these patients in the second-line setting. Although it is not FDA approved, its inclusion in the NCCN guidelines will make it more available for patients with BRAF-mutated colon cancers to receive vemurafenib.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x